Trial · NCT01816620
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
NCT01816620, Phase 2, Completed, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome. Trials, record NCT01816620. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01816620
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
- NCT number
- NCT01816620
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 41 participants, actual
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- POEMS Syndrome
- Interventions
- Lenalidomide, Dexamethasone
- First posted
- 2013-03-22
- Last updated
- 2017-04-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hematological response rate | last day of the LDx treatment regimen (up to 9 months) | |
| Primary | Neurological response rate defined by ONLS score | last day of the LDx treatment regimen (up to 9 months) | |
| Secondary | response rate of critical organs | every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months | |
| Secondary | Response rate of serum vascular endothelial growth factor (VEGF) level | every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months | |
| Secondary | Time to initial neurological response | every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months | |
| Secondary | Overall survival | From date of first diagnosis until the date of death from any cause, otherwise patients will be censored in June, 2018 (up to 5 years) | |
| Secondary | Relapse free survival | From date of first diagnosis until the date of first documented relapse or date of death from any cause, whichever came first, otherwise patients will be censored in June, 2018 (up to 5 years) | |
| Secondary | adverse events | throughout the treatment and until 30 days after the administration of the last dose of a study drug | |
| Secondary | time to the best neurological response | every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01816620
GET https://conductscience.org/api/trials/v1/NCT01816620/registered